Fig. 3.
Progression-free survival for renal cancer patients treated for metastatic disease with sunitinib or sorafenib in the first- or second-line setting (n = 106), cubilin (−) versus cubilin (+) tumors, membrane
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.